ETLI:F:F-Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.243

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-04 )

Largest Industry Peers for Others

ETFs Containing ETLI:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.45% 45% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.45% 45% F 54% F
Trailing 12 Months  
Capital Gain 3.56% 55% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.56% 53% F 52% F
Trailing 5 Years  
Capital Gain -9.04% 17% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.04% 17% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -2.11% 24% F 36% F
Dividend Return -2.11% 22% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.69% 73% C 93% A
Risk Adjusted Return -24.28% 22% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.